Force-dependent breaching of the basement membrane

Matrix Biology

Volumn 57-58, Issue , 2017, Pages 178-189

  Chang, Tammy T ^a,b   Thakar, Dhruv ^a,b   Weaver, Valerie M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Hepatocellular carcinoma; Matrix rigidity; Pancreatic cancer; Tumor invasion

Indexed keywords

BASEMENT MEMBRANE; BREAST CANCER; CANCER GROWTH; CANCER RISK; EXTRACELLULAR MATRIX; FIBROSIS; LIVER CANCER; MEDICAL LITERATURE; MOLECULAR BIOLOGY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR INVASION; BREAST TUMOR; CHEMOTAXIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; LIVER TUMOR; MAMMARY GLAND; MECHANICAL STRESS; METABOLISM; METASTASIS; PANCREAS; PANCREAS TUMOR; PATHOLOGY;

COLLAGEN; LAMININ;

BASEMENT MEMBRANE; BREAST NEOPLASMS; CHEMOTAXIS; COLLAGEN; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; LIVER; LIVER NEOPLASMS; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREAS; PANCREATIC NEOPLASMS; STRESS, MECHANICAL;

EID: 85008350831     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.12.005     Document Type: Review

References (96)

1. [1] Allred, D.C., Ductal carcinoma in situ: terminology, classification, and natural history. J. Natl. Cancer Inst. Monogr. 2010 (2010), 134–138, 10.1093/jncimonographs/lgq035.
2. [2] Lopez-Garcia, M.A., Geyer, F.C., Lacroix-Triki, M., Marchio, C., Reis-Filho, J.S., Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57 (2010), 171–192, 10.1111/j.1365-2559.2010.03568.x.
3. [3] Cowell, C.F., Weigelt, B., Sakr, R.A., Ng, C.K., Hicks, J., King, T.A., Reis-Filho, J.S., Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol. Oncol. 7 (2013), 859–869, 10.1016/j.molonc.2013.07.005.
4. [4] Allred, D.C., Wu, Y., Mao, S., Nagtegaal, I.D., Lee, S., Perou, C.M., Mohsin, S.K., O'Connell, P., Tsimelzon, A., Medina, D., Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 14 (2008), 370–378, 10.1158/1078-0432.CCR-07-1127.
5. [5] Evans, A.J., Pinder, S.E., Snead, D.R., Wilson, A.R., Ellis, I.O., Elston, C.W., The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours. Br. J. Cancer 75 (1997), 542–544.
6. [6] Page, D.L., Dupont, W.D., Rogers, L.W., Jensen, R.A., Schuyler, P.A., Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76 (1995), 1197–1200.
7. [7] Sanders, M.E., Schuyler, P.A., Dupont, W.D., Page, D.L., The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103 (2005), 2481–2484, 10.1002/cncr.21069.
8. [8] Harding, C., Pompei, F., Burmistrov, D., Welch, H.G., Abebe, R., Wilson, R., Breast cancer screening, incidence, and mortality across US counties. JAMA Intern. Med. 175 (2015), 1483–1489, 10.1001/jamainternmed.2015.3043.
9. [9] Hannemann, J., Velds, A., Halfwerk, J.B., Kreike, B., Peterse, J.L., van de Vijver, M.J., Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res., 8, 2006, R61, 10.1186/bcr1613.
10. [10] Ma, X.J., Salunga, R., Tuggle, J.T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B.M., Zhou, Y.X., Varnholt, H., Smith, B., Gadd, M., Chatfield, E., Kessler, J., Baer, T.M., Erlander, M.G., Sgroi, D.C., Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 5974–5979, 10.1073/pnas.0931261100.
11. [11] Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y.K., Argani, P., Marks, J., Richardson, A., Cooper, A., Strausberg, R., Riggins, G.J., Schnitt, S., Gabrielson, E., Gelman, R., Polyak, K., Molecular markers in ductal carcinoma in situ of the breast. Mol. Cancer Res. 1 (2003), 362–375.
12. [12] Buerger, H., Otterbach, F., Simon, R., Poremba, C., Diallo, R., Decker, T., Riethdorf, L., Brinkschmidt, C., Dockhorn-Dworniczak, B., Boecker, W., Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J. Pathol. 187 (1999), 396–402, 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L.
13. [13] Ryser, M.D., Worni, M., Turner, E.L., Marks, J.R., Durrett, R., Hwang, E.S., Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J. Natl. Cancer Inst., 108, 2016, 10.1093/jnci/djv372.
14. [14] Andea, A., Sarkar, F., Adsay, V.N., Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 16 (2003), 996–1006, 10.1097/01.MP.0000087422.24733.62.
15. [15] Hruban, R.H., Maitra, A., Goggins, M., Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 1 (2008), 306–316.
16. [16] Canto, M.I., Hruban, R.H., Fishman, E.K., Kamel, I.R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., Klein, A.P., Axilbund, J., Griffin, C., Syngal, S., Saltzman, J.R., Mortele, K.J., Lee, J., Tamm, E., Vikram, R., Bhosale, P., Margolis, D., Farrell, J., Goggins, M., Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142 (2012), 795–796, 10.1053/j.gastro.2012.01.005.
17. [17] Petrick, J.L., Kelly, S.P., Altekruse, S.F., McGlynn, K.A., Rosenberg, P.S., Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J. Clin. Oncol., 2016, 10.1200/JCO.2015.64.7412.
18. [18] Roskams, T., Kojiro, M., Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin. Liver Dis. 30 (2010), 17–25, 10.1055/s-0030-1247129.
19. [19] Nault, J.C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E.S., Bioulac-Sage, P., Roncalli, M., Zucman-Rossi, J., Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60 (2014), 1983–1992, 10.1002/hep.27372.
20. [20] Zucman-Rossi, J., Villanueva, A., Nault, J.C., Llovet, J.M., Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149 (2015), 1226–1239, 10.1053/j.gastro.2015.05.061.
21. [21] Zucman-Rossi, J., Jeannot, E., Van Nhieu, J.T., Scoazec, J.Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., Wendum, D., Chiche, L., Fabre, M., Mellottee, L., Laurent, C., Partensky, C., Castaing, D., Zafrani, E.S., Laurent-Puig, P., Balabaud, C., Bioulac-Sage, P., Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43 (2006), 515–524, 10.1002/hep.21068.
22. [22] Friedman, S.L., The cellular basis of hepatic strategies. N. Engl. J. Med. 328 (1993), 1828–1835.
23. [23] Iredale, J.P., Thompson, A., Henderson, N.C., Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim. Biophys. Acta Mol. Basis Dis. 1832 (2013), 876–883, 10.1016/j.bbadis.2012.11.002.
24. [24] Clément, B., Rescan, P.Y., Baffet, G., Loréal, O., Lehry, D., Campion, J.P., Guillouzo, A., Diseases, L., Hepatocytes may produce laminin in fibrotic liver and in primary culture. Hepatology 8 (1988), 794–803.
25. [25] Maher, J.J., Friedman, S.L., Roll, F.J., Bissell, D.M., Immunolocalization of laminin in normal rat liver and biosynthesis of laminin by hepatic lipocytes in primary culture. Gastroenterology 94 (1988), 1053–1062.
26. [26] Bianchi, F.B., Biagini, G., Ballardini, G., Cenacchi, G., Faccani, A., Pisi, E., Laschi, R., Liotta, L., Garbisa, S., Basement membrane production by hepatocytes in chronic liver disease. Hepatology 4 (1984), 1167–1172.
27. [27] Hahn, E., Wick, G., Pencev, D., Timpl, R., Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 21 (1980), 63–71, 10.1136/gut.21.1.63.
28. [28] Crissien, A.M., Frenette, C., Current management of hepatocellular carcinoma. Gastroenterol. Hepatol. (N. Y) 10 (2014), 153–161 (doi: 2014 Mar;10(3):153–61).
29. [29] Boyd, N.F., Li, Q., Melnichouk, O., Huszti, E., Martin, L.J., Gunasekara, A., Mawdsley, G., Yaffe, M.J., Minkin, S., Evidence that breast tissue stiffness is associated with risk of breast cancer. PLoS One 9 (2014), 1–8, 10.1371/journal.pone.0100937.
30. [30] Boyd, N.F., Martin, L.J., Bronskill, M., Yaffe, M.J., Duric, N., Minkin, S., Breast tissue composition and susceptibility to breast cancer. J. Natl. Cancer Inst., 102, 2010, 10.1093/jnci/djq239.
31. [31] Boyd, N.F., Martin, L.J., Yaff, M.J., Minkin, S., Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 13 (2011), 1–12.
32. [32] Bang, U.C., Benfield, T., Hyldstrup, L., Bendtsen, F., Beck Jensen, J.E., Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology 146 (2014), 989–994, 10.1053/j.gastro.2013.12.033.
33. [33] Duell, E.J., Lucenteforte, E., Olson, S.H., Bracci, P.M., Li, D., Risch, H.A., Silverman, D.T., Ji, B.T., Gallinger, S., Holly, E.A., Fontham, E.H., Maisonneuve, P., Bueno-de-Mesquita, H.B., Ghadirian, P., Kurtz, R.C., Ludwig, E., Yu, H., Lowenfels, A.B., Seminara, D., Petersen, G.M., La Vecchia, C., Boffetta, P., Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol. 23 (2012), 2964–2970, 10.1093/annonc/mds140.
34. [34] Fattovich, G., Stroffolini, T., Zagni, I., Donato, F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 2004, 10.1053/j.gastro.2004.09.014.
35. [35] Paszek, M.J., Zahir, N., Johnson, K.R., Lakins, J.N., Rozenberg, G.I., Gefen, A., Reinhart-King, C.A., Margulies, S.S., Dembo, M., Boettiger, D., Hammer, D.A., Weaver, V.M., Tensional homeostasis and the malignant phenotype. Cancer Cell 8 (2005), 241–254, 10.1016/j.ccr.2005.08.010.
36. [36] Provenzano, P.P., Inman, D.R., Eliceiri, K.W., Keely, P.J., Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 28 (2009), 4326–4343, 10.1038/onc.2009.299.
37. [37] Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., Fong, S.F., Csiszar, K., Giaccia, A., Weninger, W., Yamauchi, M., Gasser, D.L., Weaver, V.M., Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906, 10.1016/j.cell.2009.10.027.
38. [38] Rubashkin, M.G., Cassereau, L., Bainer, R., Dufort, C.C., Yui, Y., Ou, G., Paszek, M.J., Davidson, M.W., Chen, Y., Weaver, V.M., Force engages vinculin and promotes tumor progression by triphosphate. Cancer Res. 74 (2014), 4597–4612, 10.1158/0008-5472.CAN-13-3698.
39. [39] Mouw, J.K., Yui, Y., Damiano, L., Bainer, R.O., Lakins, J.N., Acerbi, I., Ou, G., Wijekoon, A.C., Levental, K.R., Gilbert, P.M., Hwang, E.S., Chen, Y.Y., Weaver, V.M., Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 20 (2014), 360–367, 10.1038/nm.3497.
40. [40] Ferraioli, G., Tinelli, C., Dal Bello, B., Zicchetti, M., Filice, G., Filice, C., G. Liver Fibrosis Study, Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 56 (2012), 2125–2133, 10.1002/hep.25936.
41. [41] Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M., Valasek, M., Lin, G., Brenner, D., Gamst, A., Ehman, R., Sirlin, C., Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928, 10.1002/hep.27362.
42. [42] Desai, S.S., Tung, J.C., Zhou, V.X., Grenert, J.P., Malato, Y., Rezvani, M., Espanol-Suner, R., Willenbring, H., Weaver, V.M., Chang, T.T., Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. Hepatology, 2016, 10.1002/hep.28450.
43. [43] Li, Z., Dranoff, J.A., Chan, E.P., Uemura, M., Sevigny, J., Wells, R.G., Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 46 (2007), 1246–1256, 10.1002/hep.21792.
44. [44] Olsen, A.L., Bloomer, S.A., Chan, E.P., Gaca, M.D., Georges, P.C., Sackey, B., Uemura, M., Janmey, P.A., Wells, R.G., Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am. J. Physiol. Gastrointest. Liver Physiol. 301 (2011), G110–G118, 10.1152/ajpgi.00412.2010.
45. [45] Yue, H.-Y., Yin, C., Hou, J.-L., Zeng, X., Chen, Y.-X., Zhong, W., Hu, P.-F., Deng, X., Tan, Y.-X., Zhang, J.-P., Ning, B.-F., Shi, J., Zhang, X., Wang, H.-Y., Lin, Y., Xie, W.-F., Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 59 (2010), 236–246, 10.1136/gut.2008.174904.
46. [46] Nishikawa, T., Bell, A., Brooks, J.M., Setoyama, K., Melis, M., Han, B., Fukumitsu, K., Handa, K., Tian, J., Kaestner, K.H., Vodovotz, Y., Locker, J., Soto-Gutierrez, A., Fox, I.J., Resetting the transcription factor network reverses terminal chronic hepatic failure. J. Clin. Invest. 125 (2015), 1533–1544, 10.1172/JCI73137.
47. [47] Bonzo, J.A., Ferry, C.H., Matsubara, T., Kim, J.-H., Gonzalez, F.J., Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J. Biol. Chem. 287 (2012), 7345–7356, 10.1074/jbc.M111.334599.
48. [48] Santangelo, L., Marchetti, A., Cicchini, C., Conigliaro, A., Conti, B., Mancone, C., Bonzo, J.A., Gonzalez, F.J., Alonzi, T., Amicone, L., Tripodi, M., The stable repression of mesenchymal program is required for hepatocyte identity: a novel role for hepatocyte nuclear factor 4??. Hepatology 53 (2011), 2063–2074, 10.1002/hep.24280.
49. [49] Lazarevich, N.L., Shavochkina, D.A., Fleishman, D.I., Kustova, I.F., Morozova, O.V., Chuchuev, E.S., Patyutko, Y.I., Deregulation of hepatocyte nuclear factor 4 (HNF4)as a marker of epithelial tumors progression. Exp. Oncol. 32 (2010), 167–171 (doi:46/862 [pii]).
50. [50] Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H.S., Chuvin, N., Parachoniak, C.A., Nagle, J.M., Perera, R.M., Lapouge, M., Deshpande, V., Zhu, A.X., Lai, A., Min, B., Hoshida, Y., Avruch, J., Sia, D., Campreciós, G., McClatchey, A.I., Llovet, J.M., Morrissey, D., Raj, L., Bardeesy, N., YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10 (2015), 1692–1707, 10.1016/j.celrep.2015.02.027.
51. [51] Ning, B.-F., Ding, J., Yin, C., Zhong, W., Wu, K., Zeng, X., Yang, W., Chen, Y.-X., Zhang, J.-P., Zhang, X., Wang, H.-Y., Xie, W.-F., Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 70 (2010), 7640–7651, 10.1158/0008-5472.CAN-10-0824.
52. [52] Lazarevich, N.L., Cheremnova, O.A., Varga, E.V., Ovchinnikov, D.A., Kudrjavtseva, E.I., Morozova, O.V., Fleishman, D.I., Engelhardt, N.V., Duncan, S.A., Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39 (2004), 1038–1047, 10.1002/hep.20155.
53. [53] Yin, C., Lin, Y., Zhang, X., Chen, Y.X., Zeng, X., Yue, H.Y., Hou, J.L., Deng, X., Zhang, J.P., Han, Z.G., Xie, W.F., Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 48 (2008), 1528–1539, 10.1002/hep.22510.
54. [54] Späth, G.F., Weiss, M.C., Hepatocyte nuclear factor 4 provokes expression of epithelial marker genes, acting as a morphogen in dedifferentiated hepatoma cells. J. Cell Biol. 140 (1998), 935–946, 10.1083/jcb.140.4.935.
55. [55] Schrader, J., Gordon-Walker, T.T., Aucott, R.L., van Deemter, M., Quaas, A., Walsh, S., Benten, D., Forbes, S.J., Wells, R.G., Iredale, J.P., Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53 (2011), 1192–1205, 10.1002/hep.24108.
56. [56] Shang, N., Arteaga, M., Zaidi, A., Stauffer, J., Cotler, S.J., Zeleznik-Le, N.J., Zhang, J., Qiu, W., FAK is required for c-met/β-catenin-driven hepatocarcinogenesis. Hepatology 61 (2015), 214–226, 10.1002/hep.27402.
57. [57] Acerbi, I., Cassereau, L., Dean, I., Shi, Q., Au, A., Park, C., Chen, Y.Y., Liphardt, J., Hwang, E.S., Weaver, V.M., Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr. Biol. 7 (2015), 1120–1134, 10.1039/c5ib00040h.
58. [58] Laklai, H., Miroshnikova, Y.A., Pickup, M.W., Collisson, E.A., Kim, G.E., Barrett, A.S., Hill, R.C., Lakins, J.N., Schlaepfer, D.D., Mouw, J.K., LeBleu, V.S., Roy, N., Novitskiy, S.V., Johansen, J.S., Poli, V., Kalluri, R., Iacobuzio-Donahue, C.A., Wood, L.D., Hebrok, M., Hansen, K., Moses, H.L., Weaver, V.M., Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med., 2016, 10.1038/nm.4082.
59. [59] Collisson, E.A., Sadanandam, A., Olson, P., Gibb, W.J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G.E., Jakkula, L., Feiler, H.S., Ko, A.H., Olshen, A.B., Danenberg, K.L., Tempero, M.A., Spellman, P.T., Hanahan, D., Gray, J.W., Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17 (2011), 500–504, 10.1038/nm.2344.
60. [60] Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A., Gingras, M., Miller, D.K., Christ, A.N., Bruxner, T.J.C., Quinn, M.C., Nourse, C., Murtaugh, L.C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M.J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P.J., Cloonan, N., Kassahn, K.S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L.N., Evers, L., Wu, J., Pinese, M., Cowley, M.J., Jones, M.D., Colvin, E.K., Nagrial, A.M., Humphrey, E.S., Chantrill, L.A., Mawson, A., Humphris, J., Giry-laterriere, M., Rooman, I., Chou, A., Pajic, M., Scarlett, C.J., Andreia, V., Kench, J.G., Lovell, J.A., Merrett, N.D., Christopher, W., Musgrove, E.A., Bailey, U.H., Hofmann, O., Sutherland, R.L., Wheeler, D.A., Waddell, N., Andrew, V., Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52, 10.1038/nature16965.
61. [61] Moffitt, R.A., Marayati, R., Flate, E.L., Volmar, K.E., Loeza, S.G.H., Hoadley, K.A., Rashid, N.U., Williams, L.A., Eaton, S.C., Chung, A.H., Smyla, J.K., Anderson, J.M., Kim, H.J., Bentrem, D.J., Talamonti, M.S., Iacobuzio-Donahue, C.A., Hollingsworth, M.A., Yeh, J.J., Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47 (2015), 1168–1178, 10.1038/ng.3398.
62. [62] Lagarrigue, F., Dupuis-Coronas, S., Ramel, D., Delsol, G., Tronchère, H., Payrastre, B., Gaits-Iacovoni, F., Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Res. 70 (2010), 6978–6987, 10.1158/0008-5472.CAN-10-0861.
63. [63] Stetler-Stevenson, W.G., Kelly, T., Lin, C.Y., Yeh, Y., Mueller, S.C., Chen, W.T., Binding and localization of Mr 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 53 (1993), 3159–3164.
64. [64] Takahara, H., Howard, L., Thompson, E.W., Sato, H., Seiki, M., Yeh, Y., Chen, W.T., Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc. Natl. Acad. Sci. U. S. A. 95 (1997), 7959–7964.
65. [65] Poincloux, R., Lizárraga, F., Chavrier, P., Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J. Cell Sci. 122 (2009), 3015–3024, 10.1242/jcs.034561.
66. [66] Deryugina, E.I., Quigley, J.P., Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25 (2006), 9–34, 10.1007/s10555-006-7886-9.
67. [67] Hagedorn, E.J., Ziel, J.W., Morrissey, M.A., Linden, L.M., Wang, Z., Chi, Q., Johnson, S.A., Sherwood, D.R., The netrin receptor DCC focuses invadopodia-driven basement membrane transmigration in vivo. J. Cell Biol. 201 (2013), 903–913, 10.1083/jcb.201301091.
68. [68] Artym, V.V., Zhang, Y., Seillier-Moiseiwitsch, F., Yamada, K.M., Mueller, S.C., Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 66 (2006), 3034–3043, 10.1158/0008-5472.CAN-05-2177.
69. [69] Linder, S., Wiesner, C., Himmel, M., Degrading devices: invadosomes in proteolytic cell invasion. Annu. Rev. Cell Dev. Biol. 27 (2011), 185–211, 10.1146/annurev-cellbio-092910-154216.
70. [70] Alexander, N.R., Branch, K.M., Parekh, A., Clark, E.S., Iwueke, I.C., Guelcher, S.A., Extracellular matrix rigidity promotes invadopodia activity. Curr. Biol. 18 (2008), 1295–1299, 10.1016/j.cub.2008.07.090.
71. [71] Parekh, A., Ruppender, N.S., Branch, K.M., Lin, J., Boyer, P.D., Candiello, J.E., Merryman, W.D., Guelcher, S.A., Weaver, A.M., Sensing and modulation of invadopodia across a wide range of rigidities. Biophys. J. 100 (2011), 573–582, 10.1016/j.bpj.2010.12.3733.
72. [72] Labernadie, A., Bouissou, A., Delobelle, P., Balor, S., Voituriez, R., Proag, A., Fourquaux, I., Thibault, C., Vieu, C., Poincloux, R., Charriere, G.M., Maridonneau-parini, I., Protrusion force microscopy reveals oscillatory force generation and mechanosensing activity of human macrophage podosomes. Nat. Commun., 5, 2014, 5343, 10.1038/ncomms6343.
73. [73] Collin, O., Tracqui, P., Stephanou, A., Usson, Y., Clément-lacroix, J., Planus, E., Spatiotemporal dynamics of actin-rich adhesion microdomains: influence of substrate flexibility. J. Cell Sci. 119 (2005), 1914–1925, 10.1242/jcs.02838.
74. [74] Dey, N., Young, B., Abramovitz, M., Bouzyk, M., Barwick, B., De, P., Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One 8 (2013), 1–17, 10.1371/journal.pone.0077425.
75. [75] Hoshino, D., Branch, K.M., Weaver, A.M., Signaling inputs to invadopodia and podosomes. J. Cell Biol. 126 (2013), 2979–2989, 10.1242/jcs.079475.
76. [76] Hoshino, D., Jourquin, J., Emmons, S.W., Miller, T., Goldgof, M., Costello, K., Tyson, D.R., Brown, B., Lu, Y., Prasad, N.K., Zhang, B., Mills, G.B., Yarbrough, W.G., Quaranta, V., Seiki, M., Weaver, A.M., Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKC a invasive signaling Axis. Sci. Signal. 5 (2012), 1–15.
77. [77] Yamaguchi, H., Yoshida, S., Muroi, E., Yoshida, N., Kawamura, M., Kouchi, Z., Nakamura, Y., Sakai, R., Fukami, K., Phosphoinositide 3-kinase signaling pathway mediated by p110a regulates invadopodia formation. J. Cell Biol. 193 (2011), 1275–1288, 10.1083/jcb.201009126.
78. [78] Mader, C.C., Oser, M., Magalhaes, M.A.O., Bravo-cordero, J.J., Condeelis, J., Koleske, A.J., Gil-henn, H., An EGFR – Src – Arg – cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 71 (2011), 1730–1741, 10.1158/0008-5472.CAN-10-1432.
79. [79] Yamaguchi, H., Lorenz, M., Kempiak, S., Sarmiento, C., Coniglio, S., Symons, M., Segall, J., Eddy, R., Miki, H., Takenawa, T., Condeelis, J., Molecular mechanisms of invadopodium formation: the role of the N-WASP–Arp2/3 complex pathway and cofilin. J. Cell Biol. 168 (2005), 441–452, 10.1083/jcb.200407076.
80. [80] Mandal, S., Johnson, K.R., Wheelock, M.J., TGF-β induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp. Cell Res. 314 (2008), 3478–3493, 10.1016/j.yexcr.2008.09.013.
81. [81] Pignatelli, J., Tumbarello, D.A., Schmidt, R.P., Turner, C.E., Hic-5 promotes invadopodia formation and invasion during TGF-b-induced epithelial–mesenchymal transition. J. Cell Biol. 197 (2012), 421–437, 10.1083/jcb.201108143.
82. [82] Diaz, B., Yuen, A., Iizuka, S., Higashiyama, S., Courtneidge, S.A., Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J. Cell Biol. 201 (2013), 279–292, 10.1083/jcb.201209151.
83. [83] Hayes, K.E., Walk, E.L., Ammer, A.G., Kelley, L.C., Martin, K.H., Weed, S.A., Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene 32 (2013), 4766–4777, 10.1038/onc.2012.513.
84. [84] Lucas, J.T. Jr., Salimath, B.P., Slomiany, M.G., Rosenzweig, S.A., Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 29 (2010), 4449–4459, 10.1038/onc.2010.185.
85. [85] Rajadurai, C.V., Havrylov, S., Zaoui, K., Vaillancourt, R., Stuible, M., Naujokas, M., Zuo, D., Tremblay, M.L., Park, M., Met receptor tyrosine kinase signals through a cortactin – Gab1 scaffold complex, to mediate invadopodia. J. Cell Sci. 125 (2012), 2940–2953, 10.1242/jcs.100834.
86. [86] Linder, S., Aepfelbacher, M., Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol. 13 (2003), 376–385, 10.1016/S0962-8924(03)00128-4.
87. [87] Murphy, D.A., Courtneidge, S.A., The “ins” and “outs” of podosomes and invadopodia: characteristics, formation and function. Nat. Rev. Mol. Cell Biol. 12 (2011), 413–426, 10.1038/nrm3141.
88. [88] Haage, A., Schneider, I.C., Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells. FASEB J. 28 (2014), 3589–3599, 10.1096/fj.13-245613.
89. [89] Neel, N.F., Rossman, K.L., Martin, T.D., Hayes, T.K., Yeh, J.J., Der, C.J., The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. Mol. Cell. Biol. 32 (2012), 1374–1386, 10.1128/MCB.06291–11.
90. [90] Welsch, T., Keleg, S., Bergmann, F., Bauer, S., Hinz, U., Schmidt, J., Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas 38 (2009), 968–976, 10.1097/MPA.0b013e3181b28d6f.
91. [91] Botta, G.P., Constitutive K-Ras(G12D power) activation of ERK2 specifically regulates oncogenesis of pancreatic cancer cells in 3D. http://search.proquest.com/docview/1037812716?accountid=50433, 2012.
92. [92] Chakraborty, S., Lakshmanan, M., Swa, H.L.F.F., Chen, J., Zhang, X., Ong, Y.S., Loo, L.S., Akıncılar, S.C., Gunaratne, J., Tergaonkar, V., Hui, K.M., Hong, W., An oncogenic role of agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat. Commun., 6, 2015, 6184, 10.1038/ncomms7184.
93. [93] Wong, C.C.L., Wong, C.M., Tung, E.K.K., Man, K., Ng, I.O.L., Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49 (2009), 1583–1594, 10.1002/hep.22836.
94. [94] Zheng, F., Liao, Y.J., Cai, M.Y., Liu, Y.H., Liu, T.H., Chen, S.P., Bian, X.W., Guan, X.Y., Lin, M.C., Zeng, Y.X., Kung, H.F., Xie, D., The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61 (2012), 278–289, 10.1136/gut.2011.239145.
95. [95] Chen, P., Xi, Q., Wang, Q., Wei, P., Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer. Med. Oncol., 31, 2014, 235, 10.1007/s12032-014-0235-x.
96. [96] Przybyla, L., Lakins, J.N., Weaver, V.M., Tissue mechanics orchestrate Wnt-dependent human embryonic stem cell differentiation. Cell Stem Cell, 2016, 1–14, 10.1016/j.stem.2016.06.018.